Teva Pharmaceuticals (NYSE:TEVA) is the world's largest manufacturer of generic drugs. The company pays a solid dividend and has been a strong performer over the past decade thanks to growing demand for low-cost medicine.
Despite that demand growth, however, the company faces a big risk to its revenue given the recent patent expiration on one of its best-selling specialty medicines. As a result, dividend investors are right to wonder whether a potential sales slide threatens Teva's dividend payout.
In the following slideshow, you'll learn more about Teva's patent risk, risk to its profitability, and how Teva compares to big drug makers like Merck and Pfizer when it comes to its dividend payout.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.